The Food and Drug Administration said the company, a subsidiary of India's Ranbaxy Laboratories Ltd., won't resume manufacturing atorvastatin until it determines the cause of the latest problem and fixes it. The recall was due to "possible contamination with very small glass particles similar to the size of a grain of sand," according to the FDA.After originally recommending that consumers consult with their pharmacist to determine if they received the recalled atorvastatin â¿¿ and if so, to stop taking it â¿¿ the agency decided Friday that it's safe to take the pills.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts